{"id":11120,"date":"2025-10-29T04:28:37","date_gmt":"2025-10-29T03:28:37","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/"},"modified":"2025-10-29T04:28:39","modified_gmt":"2025-10-29T03:28:39","slug":"linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/","title":{"rendered":"L’inhibition d’une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome"},"content":{"rendered":"
\n
\n
\n
\n<\/figure><\/div>\n<\/div>\n

Le m\u00e9lanome, la forme de cancer de la peau la plus mortelle, ne peut pas toujours \u00eatre \u00e9limin\u00e9 avec un scalpel.<\/p>\n

Les patients atteints de m\u00e9lanome \u00e0 un stade avanc\u00e9 ont souvent besoin d\u2019immunoth\u00e9rapie et de chimioth\u00e9rapie pour d\u00e9barrasser compl\u00e8tement leur corps des cellules canc\u00e9reuses. Mais m\u00eame dans ce cas, la th\u00e9rapie ne r\u00e9ussit que chez moins de la moiti\u00e9 des patients et peut entra\u00eener des effets secondaires qui nuisent \u00e0 la qualit\u00e9 de vie.<\/p>\n

Les chercheurs de l’\u00c9cole de m\u00e9decine de l’UNC et du Centre de lutte contre le cancer complet de l’UNC Lineberger ont identifi\u00e9 une solution potentielle. Dans une \u00e9tude publi\u00e9e dans le Journal d’investigation clinique<\/i>les chercheurs ont d\u00e9couvert qu’en inhibant la POZ de type speckle (SPOP), une prot\u00e9ine probl\u00e9matique, le syst\u00e8me immunitaire peut mieux combattre le m\u00e9lanome, r\u00e9duisant ainsi la croissance tumorale et renfor\u00e7ant les cellules immunitaires de l’organisme.<\/p>\n

L’\u00e9tude, premi\u00e8re du genre, montre que l’ajout d’une petite mol\u00e9cule qui bloque la prot\u00e9ine probl\u00e9matique aux traitements anticanc\u00e9reux existants, comme l’immunoth\u00e9rapie et la th\u00e9rapie cellulaire CAR-T, pourrait aider ces traitements \u00e0 mieux fonctionner chez les patients atteints d’un m\u00e9lanome difficile \u00e0 traiter.<\/p>\n

\u00ab\u00a0Pour la premi\u00e8re fois, nous avons pu confirmer que cette prot\u00e9ine sp\u00e9cifique contribue \u00e0 la croissance du m\u00e9lanome\u00a0\u00bb, a d\u00e9clar\u00e9 Pengda Liu, Ph.D., biochimiste et expert en biologie des cellules canc\u00e9reuses au UNC Lineberger Comprehensive Cancer Center. \u00ab\u00a0Nous avons \u00e9galement montr\u00e9 qu’en manipulant cette prot\u00e9ine dans des mod\u00e8les de m\u00e9lanome, nous pouvons renforcer la capacit\u00e9 de nos cellules immunitaires \u00e0 infiltrer les tumeurs solides et \u00e0 am\u00e9liorer l’efficacit\u00e9 des immunoth\u00e9rapies.\u00a0\u00bb<\/p>\n

Avant cette \u00e9tude, les chercheurs ne savaient pas si le SPOP jouait un r\u00f4le dans le m\u00e9lanome.<\/p>\n

SPOP aide le cancer \u00e0 \u00e9viter d\u2019\u00eatre d\u00e9tect\u00e9 par le syst\u00e8me immunitaire<\/h2>\n

SPOP appartient \u00e0 une famille de prot\u00e9ines appel\u00e9es E3 ubiquitine ligases. Au fil des ann\u00e9es, ces prot\u00e9ines ont \u00e9t\u00e9 associ\u00e9es \u00e0 des mutations g\u00e9n\u00e9tiques qui peuvent \u00e0 la fois augmenter et diminuer la croissance du cancer de la prostate et des reins, respectivement.<\/p>\n

Dans la premi\u00e8re partie de leur \u00e9tude, Liu et Gianpietro Dotti, MD, professeur de microbiologie et d’immunologie \u00e0 la facult\u00e9 de m\u00e9decine de l’UNC, ont d\u00e9couvert que le SPOP aide les tumeurs \u00e0 \u00e9viter la d\u00e9tection (et les attaques) du syst\u00e8me immunitaire. Ils ont confirm\u00e9 cela dans des mod\u00e8les murins et ont constat\u00e9 que lorsque le SPOP \u00e9tait \u00ab \u00e9limin\u00e9 \u00bb des tumeurs, celles-ci \u00e9taient plus violemment attaqu\u00e9es par le syst\u00e8me immunitaire, provoquant une diminution de leur taille.<\/p>\n

Liu et Dotti voulaient en savoir plus. Gr\u00e2ce \u00e0 des \u00e9tudes plus approfondies et plus techniques, les chercheurs ont d\u00e9couvert que le SPOP aide les tumeurs \u00e0 \u00e9viter la d\u00e9tection immunitaire en d\u00e9stabilisant un \u00ab capteur immunitaire \u00bb essentiel appel\u00e9 STING. STING, un type de prot\u00e9ine, peut d\u00e9tecter du mat\u00e9riel g\u00e9n\u00e9tique dangereux, comme les infections virales et les dommages \u00e0 l’ADN, et peut ensuite alerter le reste du corps d’un danger potentiel, un peu comme un syst\u00e8me de d\u00e9fense militaire.<\/p>\n

Que se passe-t-il sans SPOP<\/h2>\n

Lorsque les laboratoires Liu et Dotti ont test\u00e9 une petite mol\u00e9cule qui inhibe le SPOP, ils ont fait une d\u00e9couverte surprenante\u00a0: l’inhibiteur a non seulement restabilis\u00e9 STING, mais il a \u00e9galement activ\u00e9 davantage STING en augmentant les dommages \u00e0 l’ADN.<\/p>\n

Pour y parvenir, la petite mol\u00e9cule agit comme une colle mol\u00e9culaire qui force le SPOP et une autre prot\u00e9ine, CBX4, \u00e0 interagir les unes avec les autres, entra\u00eenant la d\u00e9gradation de CBX4 et une accumulation de dommages \u00e0 l’ADN qui attirent l’attention.<\/p>\n

En tirant parti de l’expertise du laboratoire Dotti en immunoth\u00e9rapie, les chercheurs ont pu confirmer que les inhibiteurs de SPOP aident le syst\u00e8me immunitaire de l’organisme \u00e0 combattre le m\u00e9lanome de deux mani\u00e8res\u00a0: ils aident les cellules immunitaires \u00e0 traverser les d\u00e9fenses de la tumeur et permettent aux cellules CAR-T de mieux attaquer la tumeur.<\/p>\n

De nouvelles fa\u00e7ons d\u2019administrer la chimioth\u00e9rapie<\/h2>\n

L’\u00e9quipe de recherche de Liu travaille \u00e9galement au d\u00e9veloppement de nouveaux biomat\u00e9riaux pour la lib\u00e9ration prolong\u00e9e de mol\u00e9cules et de dispositifs th\u00e9rapeutiques qui pourraient administrer des traitements sans injections fr\u00e9quentes et avec une administration de m\u00e9dicaments plus cibl\u00e9e.<\/p>\n

\u00ab\u00a0Un jour, nous esp\u00e9rons d\u00e9velopper un petit dispositif ou un patch implantable afin que les patients n’aient pas besoin de prendre de pilules ou de rester connect\u00e9s \u00e0 des sacs IV pour la chimioth\u00e9rapie\u00a0\u00bb, a d\u00e9clar\u00e9 Liu. \u00ab\u00a0Nous voulons simplement utiliser tout ce que nous pouvons faire pour am\u00e9liorer l’efficacit\u00e9 th\u00e9rapeutique et la qualit\u00e9 de vie des patients atteints de cancer.\u00a0\u00bb<\/p>\n

<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Le m\u00e9lanome, la forme de cancer de la peau la plus mortelle, ne peut pas<\/p>\n","protected":false},"author":1,"featured_media":11121,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[311,2923,386,1682,284,2909,7385,49,6748,5615,3594,1033,1063],"class_list":["post-11120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-aide","tag-car","tag-cellulaire","tag-combattre","tag-dune","tag-efficacement","tag-immunotherapies","tag-les","tag-linhibition","tag-melanome","tag-problematique","tag-proteine","tag-therapie","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"\nL'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Le m\u00e9lanome, la forme de cancer de la peau la plus mortelle, ne peut pas\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T03:28:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T03:28:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"1058\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"L’inhibition d’une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome\",\"datePublished\":\"2025-10-29T03:28:37+00:00\",\"dateModified\":\"2025-10-29T03:28:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\"},\"wordCount\":860,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg\",\"keywords\":[\"aide\",\"car\",\"cellulaire\",\"Combattre\",\"dune\",\"efficacement\",\"immunoth\u00e9rapies\",\"Les\",\"linhibition\",\"m\u00e9lanome\",\"probl\u00e9matique\",\"prot\u00e9ine\",\"th\u00e9rapie\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\",\"name\":\"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg\",\"datePublished\":\"2025-10-29T03:28:37+00:00\",\"dateModified\":\"2025-10-29T03:28:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg\",\"width\":1280,\"height\":1058,\"caption\":\"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L’inhibition d’une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/","og_locale":"fr_FR","og_type":"article","og_title":"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome - RVH-Synergie.org","og_description":"Le m\u00e9lanome, la forme de cancer de la peau la plus mortelle, ne peut pas","og_url":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/","og_site_name":"RVH-Synergie","article_published_time":"2025-10-29T03:28:37+00:00","article_modified_time":"2025-10-29T03:28:39+00:00","og_image":[{"width":1280,"height":1058,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"L’inhibition d’une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome","datePublished":"2025-10-29T03:28:37+00:00","dateModified":"2025-10-29T03:28:39+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/"},"wordCount":860,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg","keywords":["aide","car","cellulaire","Combattre","dune","efficacement","immunoth\u00e9rapies","Les","linhibition","m\u00e9lanome","probl\u00e9matique","prot\u00e9ine","th\u00e9rapie"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/","url":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/","name":"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg","datePublished":"2025-10-29T03:28:37+00:00","dateModified":"2025-10-29T03:28:39+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1761708517_Linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie.jpg","width":1280,"height":1058,"caption":"L'inhibition d'une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/linhibition-dune-proteine-problematique-aide-les-immunotherapies-et-la-therapie-cellulaire-car-t-a-combattre-plus-efficacement-le-melanome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"L’inhibition d’une prot\u00e9ine probl\u00e9matique aide les immunoth\u00e9rapies et la th\u00e9rapie cellulaire CAR T \u00e0 combattre plus efficacement le m\u00e9lanome"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/11120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=11120"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/11120\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/11121"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=11120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=11120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=11120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}